Funding academic clinical research: a structured but demanding landscape

In France, academic clinical research relies largely on competitive public funding. National calls for projects (funding calls) are the main mechanism supporting clinical studies run by university hospitals (CHU), comprehensive cancer centers (CLCC), and academic institutions.

Understanding how these calls work, their selection criteria, and what is expected of a competitive application is a key skill for any investigator looking to grow their research activity.

Overview of the main national calls for projects

PHRC — Programme Hospitalier de Recherche Clinique (the national hospital clinical research funding program)

The PHRC is the oldest and most structuring funding mechanism for interventional clinical research in France. It is managed by the French Directorate-General for Healthcare Provision (DGOS) and comprises three strands:

PHRC-I (interregional): projects run by a healthcare institution, with interregional multicenter recruitment. Typical funding: 200,000 to 1,500,000 €.
PHRC-K (cancer): projects dedicated to oncology research, co-funded with the INCa. Same structural characteristics as the PHRC-I.
PHRC-N (national): projects with major public-health stakes run by national-level teams, with higher funding. Reviewed by the national level of the DGOS.

The PHRC funds interventional research exclusively (RIPH 1 and RIPH 2). Purely observational studies are not eligible.

PREPS — Programme de Recherche sur la Performance du Système de Soins (the research program on healthcare system performance)

The PREPS is aimed at projects evaluating care organizations, patient care pathways, or public-health strategies. It accepts a variety of designs, including medico-economic studies and studies of clinical practices. It is a less competitive call in terms of the number of applications than the PHRC, with specific review criteria geared toward organizational and medico-economic impact.

PHRIP — Programme Hospitalier de Recherche Infirmière et Paramédicale (the hospital nursing and allied-health research program)

The PHRIP funds research projects run by allied-health professionals (nurses, physiotherapists, speech therapists, etc.) in connection with their clinical practice. It is managed by the DGOS and follows a timeline similar to the PHRC. Studies can be interventional or observational and must address a clinical question directly related to allied-health practice. The PHRIP is accessible without a principal medical co-investigator, which makes it a singular mechanism in the landscape of national calls.

PRME — Programme de Recherche sur les Maladies Rares (the rare diseases research program)

The PRME is dedicated to clinical research projects focusing on rare diseases. It is co-managed by the DGOS and the French Directorate-General for Health (DGS), in connection with the relevant rare-diseases network. Eligible projects must fall within the scope of the National Rare Diseases Plan and be run by teams involved in labeled reference or competence centers (CRMR, CCMR). The methodological requirements are adapted to the sample-size constraints specific to rare diseases.

Appel Émergence — Support for early-career investigators

Several funding programs are dedicated to early-career investigators looking to develop their first line of independent clinical research. These calls, run depending on the region by the GIRCI, the CHU, or certain foundations, fund feasibility studies or pilot projects with a modest budget (generally 30,000 to 100,000 €). Their aim is to enable an early-career investigator to build solid preliminary data with a view to a later submission to the competitive national calls (PHRC, PREPS). The letter of intent is often the central piece of the application.

Other complementary mechanisms

RHU — Recherche Hospitalo-Universitaire en santé (hospital-university health research): a program of the French National Research Agency (ANR) (Investissements d'Avenir) funding ambitious projects at the interface of clinical care, basic research, and industrial innovation (3 to 10 M€). Reserved for consortia formed with industrial partners; it requires 12 to 18 months of preparation and strong institutional backing.
FHU — Fédération Hospitalo-Universitaire (hospital-university federation): a cooperation structure between a CHU and a university, accredited by the ministry, aimed at intensifying translational research on a given theme. The FHU label opens access to dedicated funding and strengthens teams' visibility in competitive calls.
IHU — Institut Hospitalo-Universitaire (hospital-university institute): institutes of excellence at the care–research–training interface, created under the Investissements d'Avenir framework. IHUs have their own funding and integrated sponsorship structures — they constitute both a research environment and a funding lever for the projects run within them.
INSERM / INCa / ANR calls: depending on the theme and the disciplinary positioning.
Regional calls: some ARS (regional health agencies) and regional councils fund projects with a local scope.

Typical timeline of a national call for projects (PHRC)

Step	Indicative period
Publication of the call (DGOS)	September — October
Submission of the letter of intent (LOI)	October — November
Feedback on the letter of intent (invitation to submit)	November — December
Deadline for submitting the full application	January — February
Review by experts	February — April
Results and notification	June — July
Effective start of funding	Q4 of year N or Q1 of N+1

This timeline means that the scientific and regulatory maturation of the project must be substantially advanced as early as the autumn preceding submission. Starting to write the application in December for a January deadline is a high-risk strategy.

What review panels assess: the selection criteria

Scientific relevance and originality: is the question raised still unresolved? Does it make a significant contribution to practice?
Methodological quality: is the design suited to the question? Are the statistical hypotheses justified? Is the sample-size calculation rigorous?
Feasibility: is the planned recruitment realistic? Has the network of centers been established?
Expected impact: how will the results change clinical practice?
Quality of the team and the environment: does the principal investigator have demonstrated experience? Is the clinical research office (DRCI) structured to ensure sponsorship?
Consistency and integrity of the budget: review panels pay growing attention to the alignment between the study's objectives, the design, the sample size, and the requested budget. An underestimated budget is perceived as a risk of non-completion; an oversized budget without justification undermines the credibility of the application.

The mistakes that sink a competitive application

Common mistake	Why it eliminates the application
Research question too broad	The panel cannot assess feasibility or originality without precise scoping
Underestimated sample size	An optimistic power calculation signals a lack of awareness of the real constraints of recruitment
Incomplete network of centers at submission	A multicenter project "still being established" does not convince a panel of its feasibility
Clinical impact not articulated	"Improving care" is not an impact — the panel expects a precise answer to "what will change?"
Poorly sized or inconsistent budget	An underestimated budget signals an underestimation of real costs; an overestimated budget without justification undermines credibility — both are penalizing
Application prepared in a rush	Inconsistencies between sections and missing appendices signal an immature application

Practical recommendations for a competitive application

Plan 12 to 18 months ahead: scientific maturity, building the network, and regulatory preparation take time.
Assemble the team from the design phase: methodologist, biostatistician, and DRCI contact must be integrated before writing the application, not after.
Rely on real feasibility data: active-caseload surveys, registry data, hospital data — not theoretical estimates.
Read the review reports from previous calls: the DGOS publishes summaries that help identify the most discriminating criteria from one year to the next.
Do not underestimate the impact section: it is often the least well-written section, yet one of the most heavily weighted in the review.

PHRC, PREPS, PHRIP, PRME: clinical research funding calls